AU2002306736A1 - A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same - Google Patents

A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same

Info

Publication number
AU2002306736A1
AU2002306736A1 AU2002306736A AU2002306736A AU2002306736A1 AU 2002306736 A1 AU2002306736 A1 AU 2002306736A1 AU 2002306736 A AU2002306736 A AU 2002306736A AU 2002306736 A AU2002306736 A AU 2002306736A AU 2002306736 A1 AU2002306736 A1 AU 2002306736A1
Authority
AU
Australia
Prior art keywords
immunogenicity
replication
delivery
same
linking antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002306736A
Inventor
Chien-Fu Hung
Tzyy-Choou Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU2002306736A1 publication Critical patent/AU2002306736A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002306736A 2001-03-16 2002-03-18 A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same Abandoned AU2002306736A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27685401P 2001-03-16 2001-03-16
US60/276,854 2001-03-16
PCT/US2002/008033 WO2002074920A2 (en) 2001-03-16 2002-03-18 A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same

Publications (1)

Publication Number Publication Date
AU2002306736A1 true AU2002306736A1 (en) 2002-10-03

Family

ID=23058342

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002306736A Abandoned AU2002306736A1 (en) 2001-03-16 2002-03-18 A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same

Country Status (2)

Country Link
AU (1) AU2002306736A1 (en)
WO (1) WO2002074920A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
ES2454640T3 (en) 2000-08-03 2014-04-11 Johns Hopkins University Molecular vaccine that carries a chaperone polypeptide from the endoplasmic reticulum to an antigen
AU2002258631B2 (en) 2001-03-27 2007-05-17 New York University Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors
WO2004098526A2 (en) 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
US7910093B2 (en) 2003-08-19 2011-03-22 New York University Method for detecting cancer cells and monitoring cancer therapy
AU2005322960A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
US7303898B2 (en) 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
CN101036784B (en) * 2007-03-09 2010-11-10 中国人民解放军第二军医大学 Toxicity T cell position vaccine of the cell for treating Hepatitis B and the preparing method
EP2590670B1 (en) 2010-07-06 2017-08-23 GlaxoSmithKline Biologicals SA Methods of raising an immune response by delivery of rna
RS54489B1 (en) 2010-07-06 2016-06-30 Glaxosmithkline Biologicals Sa Liposomes with lipids having an advantageous pka-value for rna delivery
PT2591114T (en) 2010-07-06 2016-08-02 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of rna
PL3970742T3 (en) 2010-08-31 2022-09-19 Glaxosmithkline Biologicals S.A. Pegylated liposomes for delivery of immunogen-encoding rna
US20140030292A1 (en) 2010-10-11 2014-01-30 Novartis Ag Antigen delivery platforms
US20190002838A1 (en) * 2015-06-19 2019-01-03 Seracare Life Sciences, Inc. Sindbis control virus
WO2019147925A1 (en) * 2018-01-26 2019-08-01 Nantcell, Inc. Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses

Also Published As

Publication number Publication date
WO2002074920A3 (en) 2003-09-25
WO2002074920A2 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
AU2003235707A1 (en) Immunogenic preparations and vaccines on the basis of mrna
AU2002306736A1 (en) A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same
AU7089600A (en) Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein
EP1673447A4 (en) Immunogenic composition and method of developing a vaccine based on portions of the hiv matrix protein
AU2003221704A1 (en) Immunogenic peptides, and method of identifying same
AU2001256373A1 (en) Syringe and method for the use thereof
AU2003270149A1 (en) Akap18 delta, a novel splicing variant of a protein kinase a anchor protein and the use of the same
EP1261623A4 (en) New retinol derivatives, the method of preparations and the uses thereof
AU2002305028A1 (en) West nile virus epitopes and uses thereof
AU2002233457A1 (en) Non-glycosylated peptides derived from the rsv g protein and use thereof in a vaccine
AU2002228347A1 (en) Malaria plasmodium antigen polypeptide SE36, method of purifying the same and vaccine and diagnostic with the use of the thus obtained antigen
AU2002255649A1 (en) Band 3 antigenic peptides, malaria polypeptides and uses thereof
AU2002212049A1 (en) Novel silicone material, its preparation method and the use thereof
AU2001233576A1 (en) A novel recombinant staphylokinase derivant and its preparation method and application thereof
WO2004058188A3 (en) Vaccine compositions and methods
AU2001236817A1 (en) Insulin homolog polypeptide zins4
AU5851296A (en) Malaria peptides and vaccines
AU2002320079A1 (en) Vaccines, immunotherapeutics and methods of using the same
EP1490396A4 (en) Immunogenic hiv peptides for use as reagents and vaccines
AU2001261534A1 (en) The meca-79 antigen and related methods
AU2002325783A1 (en) Vaccine formulation potentiated by the combination of a DNA and an antigen
AU2001269640A1 (en) Vaccine against the influenza virus and method for producing said virus vaccine
AU5502499A (en) A new gene of human lysoenzyme, the encoding polypeptide and methods for preparing them
AU2002364340A1 (en) High-porosity materials and method for preparing same
AU2002259099A1 (en) Immunogenic tumor antigens: nucleic acids and polypeptides encoding the same and methods of use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase